Ten63 Therapeutics Unveils BEYOND-Alpha: A New Venture with Chugai Pharmaceutical
Ten63 Therapeutics Unveils BEYOND-Alpha
In a groundbreaking move to enhance pharmaceutical development, Ten63 Therapeutics, Inc. has launched its latest initiative, BEYOND-Alpha. This early adopter program is set to partner with select pharmaceutical companies to leverage the capabilities of Ten63's advanced computational drug design platform, BEYOND. The first participant in this program is recognized as Chugai Pharmaceutical Co., Ltd., a prominent name in the drug discovery field.
The primary aim of the BEYOND-Alpha program is to provide a tailored approach that allows a select group of early participants to implement the BEYOND platform across a variety of challenging drug targets. This innovative strategy is critical; conventional drug discovery methods often struggle with certain targets that are deemed historically undruggable. According to Marcel Frenkel, Ph.D., Co-Founder and CEO of Ten63 Therapeutics, this new program highlights how artificial intelligence is transforming the landscape of drug discovery. By utilizing computational molecular design, the BEYOND platform is capable of scaling operations far beyond traditional experimental methods.
As part of this partnership, Ten63 will focus on targets nominated by Chugai that present difficulties for traditional small-molecule drug discovery approaches. Utilizing its proprietary technology, BEYOND will generate and optimize molecular structures specifically designed for each of these targets. Chugai will then have the opportunity to negotiate further research, development, and commercialization agreements for the successful structures developed through this initiative. This partnerships aligns perfectly with Chugai's reputation for innovation within the pharmaceutical landscape. Frenkel commended Chugai for their exceptional track record and their dedication to pushing scientific boundaries, citing them as the ideal first participant in the BEYOND-Alpha program.
The launch of BEYOND-Alpha also builds upon a previous strategic investment from Chugai's venture arm, which had expressed confidence in Ten63's mission during a financing round in February 2026. This collaboration underscores a mutual commitment to addressing unmet medical needs through cutting-edge science and technology.
The BEYOND Platform
BEYOND represents a significant advancement in computational drug design that specifically addresses generative chemistry challenges. It is tailored to maintain high accuracy when dealing with both low-data scenarios and difficult targets. In recent studies, designs generated via the BEYOND platform achieved hit rates ranging from an impressive 11% to a remarkable 75% across various protein targets. These studies included targets where other leading methods had previously yielded minimal confirmed binders. Remarkably, hit identification was accomplished by synthesizing and testing fewer than twenty molecules for each program.
BEYOND leverages a combination of high-fidelity physics-based simulation and AI technologies, enabling Ten63 to explore an estimated 100 trillion synthetically accessible molecules. This allows for the design of drug candidates against protein targets that have previously been deemed intractable, including those without traditional binding pockets.
Overview of the BEYOND-Alpha Program
The BEYOND-Alpha initiative aims to demonstrate the scalability of Ten63's BEYOND platform across various pharmaceutical discovery portfolios. By allowing a limited number of pharmaceutical partners the chance to apply BEYOND to complex drug targets, Ten63 provides participants the ability to assess numerous potential molecular candidates before selecting those to pursue for further development and possible licensing deals.
About Ten63 Therapeutics
Located in Research Triangle, North Carolina, Ten63 Therapeutics is a pioneering AI-driven drug discovery company that emerged from academic institutions, Duke University and TTIC. With a clear focus on utilizing its BEYOND computational platform for generative chemistry, Ten63 seeks to develop unique and effective therapeutics that can address significant medical challenges in today's healthcare landscape.
About Chugai Pharmaceutical Co., Ltd.
Headquartered in Tokyo, Chugai Pharmaceutical is known for its robust drug discovery capabilities and commitment to innovation in the pharmaceutical field. With a focus on utilizing cutting-edge technologies, Chugai aims to bring forward groundbreaking pharmaceutical products that respond to unmet medical needs. Through its connection to the Roche Group, Chugai continues to play an essential role in the global healthcare landscape, striving to deliver value through innovative solutions.
In conclusion, the unfolding partnership between Ten63 Therapeutics and Chugai Pharmaceutical under the BEYOND-Alpha initiative represents a significant step toward redefining the future of pharmaceutical discovery, combining AI and innovative design to create therapeutic solutions previously thought unattainable. As the pharmaceutical landscape continues to evolve, such collaborations highlight the important role of technology in advancing healthcare outcomes.